实用肝脏病杂志 ›› 2026, Vol. 29 ›› Issue (1): 121-124.doi: 10.3969/j.issn.1672-5069.2026.01.031

• 肝癌 • 上一篇    下一篇

能谱CT虚拟平扫评估TACE术治疗肝细胞癌患者临床效果价值研究*

王梦云, 赵青, 赵正宇, 左小华, 刘红阳   

  1. 223001 江苏省淮安市 徐州医科大学附属淮安医院/淮安市第二人民医院影像科(王梦云,赵青,赵正宇,刘红阳);疼痛科(左小华)
  • 收稿日期:2025-08-18 出版日期:2026-01-10 发布日期:2026-02-04
  • 通讯作者: 刘红阳,E-mail:HongYangLiu2010@163.com
  • 作者简介:王梦云,女,32岁,医学硕士,住院医师。E-mail:MengyunWang2018@163.com
  • 基金资助:
    *江苏省中医药管理局中医药科技发展计划项目(编号:MS2022107)

Clinical application of spectral CT virtual non-contrast in evaluating postoperative efficacy of TACE in patients with hepatocellular carcinoma

Wang Mengyun, Zhao Qing, Zhao Zhengyu, et al   

  1. Department of Radiology, Second People's Hospital,Affiliated to Xuzhou Medical University, Huai’an, 223001, Jiangsu Province, China
  • Received:2025-08-18 Online:2026-01-10 Published:2026-02-04

摘要: 目的 探讨能谱CT虚拟平扫(VNC)评估经肝动脉化疗栓塞(TACE)术治疗肝细胞癌(HCC)患者临床效果的价值。方法 2023年1月~2025年5月我院收治的107例HCC患者,均接受TACE治疗。在治疗前后行能谱CT扫描,经后处理获取病灶真实平扫(TNC)和3期VNC图像,记录病灶TNC和3期VNC CT值。使用全自动化学发光免疫分析仪检测血清甲胎蛋白(AFP)水平。结果 在治疗后3个月,参照mRECIST评价标准本组107例HCC患者获得客观缓解(OR)62例(57.9%),疾病稳定或进展45例(42.1%);在治疗后,OR组病灶TNC、动脉期、门静脉期和延迟期VNC CT值分别为(32.5±3.0)HU、(35.0±2.5)HU、(34.1±1.9)HU和(33.5±2.0)HU,均显著低于非OR组【分别为(37.2±4.3)HU、(82.4±7.1)HU、(80.6±9.7)HU和(70.3±9.2)HU,P<0.05】;治疗前,两组血清AFP水平分别为(749.2±53.1)ng/mL和(747.6±48.5)ng/mL(P>0.05);治疗后,OR组血清AFP水平为(87.4±8.3)ng/mL,显著低于非OR组【(453.2±39.4)ng/mL,P<0.05】。结论 采用VNC技术可替代TNC较好地评估TACE术治疗的HCC患者的临床疗效,可有效减少辐射量,具有较好的临床实用价值。

关键词: 肝细胞癌, 经肝动脉化疗栓塞, 能谱CT虚拟平扫, 治疗, 评估

Abstract: Objective The aim of this study was to explore the clinical application of spectral CT virtual non-contrast (VNC) in evaluating postoperative efficacy of transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC). Methods A total of 107 patients with HCC were encountered in our hospital between January 2023 and May 2025, and all underwent TACE treatment. All patients underwent spectral CT scans before and after treatment to obtain true non-contrast (TNC) of lesions and VNC images at arterial phase, portal vein phase, and delayed phase by through post-processing. CT values of lesion by TNC and VNC at three-phases were recorded and compared. Serum alpha-fetoprotein (AFP) levels were detected by full-automatic chemiluminescence immunoanalyzer. Results By end of three-month treatment, Objective remission (OR) judged by mRECIST was found in 62 cases (57.9%)and stable disease or disease progression in 45 cases (42.1%) in our series; after treatment, the TNC, VNC CT value of lesions at arterial phase, portal vein phase, and delayed phase in patients with OR were(32.5±3.0)HU, (35.0±2.5)HU, (34.1±1.9)HU and (33.5±2.0)HU, all significantly lower than [(37.2±4.3)HU, (82.4±7.1)HU, (80.6±9.7)HU and (70.3±9.2)HU, respectively, P<0.05] in those with non-OR; at presentation, serum AFP levels in the two groups were (749.2±53.1)ng/mL and (747.6±48.5)ng/mL(P>0.05), while after treatment, serum AFP level in OR group was (87.4±8.3)ng/mL, much lower than [(453.2±39.4)ng/mL,P<0.05] in non-OR group. Conclusion VNC could be an alternative tool for TNC to satisfactorily evaluate the curative efficacy of TACE in HCC patients, which might effectively reduce radiation doses, with a good clinical application.

Key words: Hepatocellular carcinoma, Transcatheter arterial chemoembolization, Spectral CT virtual non-contrast, Therapy, Evaluation